EUVIMEDEUVIMED entdecken
Open Access

A picomolar inhibitor of the Plasmodium falciparum IPP pathway

Stephanie Kabeche iD, Thomas Braukmann, Jon Doenier, Thomas Meister iD, Ellen Yeh iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01238-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Stephanie Kabeche und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Stanford University School of Medicine, Stanford, California, USA. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HHS | National Institutes of Health (NIH), HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We identified MMV026468 as a picomolar inhibitor of blood-stage Plasmodium falciparum . Phenotyping assays, including isopentenyl diphosphate rescue of parasite growth inhibition, demonstrated that it targets MEP isoprenoid precursor biosynthesis. MMV026468-treated parasites showed an overall decrease in MEP pathway intermediates, which could result from inhibition of the first MEP enzyme DXS or steps prior to DXS such as regulation of the MEP pathway. Selection of MMV026468-resistant parasites lacking DXS mutations suggested that other targets are possible. The identification of MMV026468 could lead to a new class of antimalarial isoprenoid inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumAntimalarialsOrganophosphorus CompoundsHemiterpenesDrug ResistanceHumansErythritol

Stichwörter der Autor:innen

MEP pathwayantimalarial agentsapicoplastdrug discoveryisoprenoid biosythesismalaria

Substanzen

AntimalarialsOrganophosphorus CompoundsHemiterpenesisopentenyl pyrophosphateErythritol

Autor:innen und Institutionen

  • Department of Biochemistry, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California, USA.
  • Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, California, USA.
  • Chan Zuckerberg Biohub, San Francisco, California, USA.

ORCID-Profile: Stephanie Kabeche, Thomas Meister, Ellen Yeh

Förderung

  • HHS | National Institutes of Health (NIH)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • NIAID NIH HHS
  • NHGRI NIH HHS
  • Wellcome Trust
  • Burroughs Wellcome Fund (BWF)
  • Chan Zuckerberg Initiative (CZI)

Zitieren

APA

Kabeche, S., Braukmann, T., Doenier, J., Meister, T., & Yeh, E. (2024). A picomolar inhibitor of the Plasmodium falciparum IPP pathway. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01238-23

Vancouver

Kabeche S, Braukmann T, Doenier J, Meister T, Yeh E. A picomolar inhibitor of the Plasmodium falciparum IPP pathway. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01238-23

BibTeX
@article{Kabeche2024,
  author = {Kabeche, Stephanie and Braukmann, Thomas and Doenier, Jon and Meister, Thomas and Yeh, Ellen},
  title = {A picomolar inhibitor of the Plasmodium falciparum IPP pathway},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01238-23}
}
Kostenlos starten →